Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr 27;30 Suppl 1(Suppl 1):A7-14.
doi: 10.1016/j.vaccine.2011.12.096.

Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030

Deborah E Atherly  1 , Kristen D C Lewis, Jacqueline Tate, Umesh D Parashar, Richard D Rheingans
Affiliations

Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030

Deborah E Atherly et al. Vaccine. .

Abstract

Rotavirus is the leading cause of diarrheal disease in children under 5 years of age. It is responsible for more than 450,000 deaths each year, with more than 90% of these deaths occurring in low-resource countries eligible for support by the GAVI Alliance. Significant efforts made by the Alliance and its partners are providing countries with the opportunity to introduce rotavirus vaccines into their national immunization programs, to help prevent childhood illness and death. We projected the cost-effectiveness and health impact of rotavirus vaccines in GAVI-eligible countries, to assist decision makers in prioritizing resources to achieve the greatest health benefits for their populations. A decision-analytic model was used to project the health outcomes and direct costs of a birth cohort in the target population, with and without a rotavirus vaccine. Current data on disease burden, vaccine efficacy, immunization rates, and costs were used in the model. Vaccination in GAVI-eligible countries would prevent 2.46 million childhood deaths and 83 million disability-adjusted life years (DALYs) from 2011 to 2030, with annual reductions of 180,000 childhood deaths at peak vaccine uptake. The cost per DALY averted is $42 for all GAVI countries combined, over the entire period. Rotavirus vaccination would be considered very cost-effective for the entire cohort of GAVI countries, and in each country individually, as cost-effectiveness ratios are less than the gross domestic product (GDP) per capita. Vaccination is most cost-effective and has the greatest impact in regions with high rotavirus mortality. Rotavirus vaccination in GAVI-eligible countries is very cost-effective and is projected to substantially reduce childhood mortality in this population.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflict of Interest: The authors have no conflicts to declare.

Figures

Figure 1.
Figure 1.
Annual and cumulative deaths averted: 2011 – 2030
Figure 2.
Figure 2.
Annual cost-effectiveness ratio and number of infants vaccinated over time
See this image and copyright information in PMC

References

    1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010. Jun 5;375(9730):1969–87. - PubMed
    1. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009. Nov 1;200 Suppl 1:S9–S15. - PubMed
    1. Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010. Feb;125(2):e199–207. - PubMed
    1. Cortese MM, Tate JE, Simonsen L, Edelman L, Parashar UD. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J 2010. Jun;29(6):489–94. - PubMed
    1. Snelling TL, Schultz R, Graham J, Roseby R, Barnes GL, Andrews RM, et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis 2009. Aug 1;49(3):428–31. - PubMed

Publication types

MeSH terms

Substances